Managing dopamine agonist withdrawal syndrome in Parkinson's disease

Lindahl, Andrea J MA, MD, FRCP
MacMahon, Douglas G FRCP

Dr Lindahl is a Consultant Neurologist and Dr MacMahon is a Consultant Physician at University Hospitals, Coventry and Warwickshire NHS Trust, Coventry

Progress in Neurology and Psychiatry 15(4):p 4-5, July-August 2011.

Dopamine agonist withdrawal syndrome (DAWS) has recently been named in theArchives of Neurology.It describes a cluster of symptoms occurring in Parkinson's disease patients with impulse control disorders on tapering down or withdrawal of their dopamine agonist. Drs Lindahl and MacMahon discuss the risk factors for the development of DAWS and some approaches to its management.